1
Van, Berkel Patrick Hendrikus Cornelis, Brus Ronald Hendrik Peter, Bout Abraham, Logtenberg Ton: Recombinant production of mixtures of antibodies. Crucell Holland, Van, Berkel Patrick Hendrikus Cornelis, Brus Ronald Hendrik Peter, Bout Abraham, Logtenberg Ton, KLEIN Bart, January 29, 2004: WO/2004/009618 (52 worldwide citation)

The invention provides methods for producing mixtures of antibodies from a single host cell clone. Thereto a nucleic acid sequence encoding a light chain, and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The antibodies in the mixtures according to ...


2
Opstelten Dirk Jan Elbertus, Kapteyn Johan Christiaan, Passier Petrus Christianus Johannes Josephus, Brus Ronald Hendrik Peter, Bout Abraham: Methods and means for producing proteins with predetermined post-translational modifications. Crucell Holland, Opstelten Dirk Jan Elbertus, Kapteyn Johan Christiaan, Passier Petrus Christianus Johannes Josephus, Brus Ronald Hendrik Peter, Bout Abraham, CRUCELL HOLLAND, May 8, 2003: WO/2003/038100 (4 worldwide citation)

The present invention provides methods for identifying, selecting and obtaining mammalian cells that are capable of producing proteinaceous molecules comprising predetermined post-translational modifications, wherein said post-translational modifications are brought about by the mammalian cell in wh ...


3
Hateboer Guus, Verhulst Karina Cornelia, Schouten Govert Johan, Uytdehaag Alphonsus Gerardus Cornelis Maria, Bout Abraham: Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein. Crucell Holland, Hateboer Guus, Verhulst Karina Cornelia, Schouten Govert Johan, Uytdehaag Alphonsus Gerardus Cornelis Maria, Bout Abraham, PRINS A W, October 26, 2000: WO/2000/063403 (2 worldwide citation)

The present invention provides methods and compositions for the production of recombinant proteins in a human cell line, using sequences encoding at least one E1 protein of an adenovirus where the cells does not encode a structural adenoviral protein from its genome. The methods and compositions are ...


4
Fallaux Frits Jacobus, Hoeben Robert Cornelis, Bout Abraham, Valerio Domenico, Van Der Eb Alex Jan: Packaging systems for human recombinant adenovirus to be used in gene therapy. Introgene, Rijksuniversiteit Leiden, Fallaux Frits Jacobus, Hoeben Robert Cornelis, Bout Abraham, Valerio Domenico, Van Der Eb Alex Jan, SMULDERS Th A H J, January 3, 1997: WO/1997/000326 (2 worldwide citation)

The invention provides improved methods and products based on adenoviral materials which can advantageously be used in for instance gene therapy. In one aspect an adenoviral vector is provided which has no overlap with a suitable packaging cell line which is another aspect of invention. This combina ...


5
Bout Abraham, Havenga Menzo Jans Emco, Vogels Ronald: Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35. Crucell Holland, Bout Abraham, Havenga Menzo Jans Emco, Vogels Ronald, PRINS A W, November 23, 2000: WO/2000/070071 (1 worldwide citation)

The serotypes differ in their natural tropism. The adenovirus serotypes (2, 4, 5 and 7) all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes (40 and 41) have a natural affiliation towards the gastrointestinal tract. The serotypes described above ...


6
Vogels Ronald, Bout Abraham: Means and methods for the production of adenovirus vectors. Crucell Holland, Vogels Ronald, Bout Abraham, December 18, 2003: WO/2003/104467 (1 worldwide citation)

The invention relates to methods and means for the production of adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more pro ...


7
Bout Abraham, Valerio Domenico, Schouten Govert Johan, Fallaux Frits Jacobus, Hoeben Robert Cornelis, Van Der Eb Alex Jan: Means and methods for nucleic acid transfer. Introgene, Rijksuniversiteit Leiden, Bout Abraham, Valerio Domenico, Schouten Govert Johan, Fallaux Frits Jacobus, Hoeben Robert Cornelis, Van Der Eb Alex Jan, PRINS A W, February 1, 2001: WO/2001/007571

Cells capable of at least, in part, complementing adenovirus E2A function of an adenovirus defective in E2A function. Such cells include a nucleic acid encoding adenovirus E2A or a functional part, derivative and/or analogue thereof, integrated into the genome of the cell. Preferably, the cell has E ...


8
Otte Arie Pieter, Kwaks Theodorus Hendrikus Jacobus, Sewalt Richard George Antonius Bernardus, Van, Blokland Henricus Johannes Maria, Bout Abraham: Improved protein production. Chromagenics, Crucell Holland, Otte Arie Pieter, Kwaks Theodorus Hendrikus Jacobus, Sewalt Richard George Antonius Bernardus, Van, Blokland Henricus Johannes Maria, Bout Abraham, KLEIN Bart, June 30, 2005: WO/2005/059149

The invention provides E1-immortalized retina cells comprising a recombinant protein expression unit which unit comprises a promoter functionally linked to an open reading frame encoding at least one protein of interest, characterized in that said expression unit comprises at least one element impro ...


9
Havenga Menzo Jans Emco, Vogels Ronald, Bout Abraham: Transduction of chondrocytes using adenoviral vectors. Crucell Holland, Havenga Menzo Jans Emco, Vogels Ronald, Bout Abraham, CRUCELL HOLLAND, February 14, 2002: WO/2002/012523

The present invention relates to a gene delivery vehicle comprising a recombinant adenovirus having a tropism for a primary human chondrocyte. By efficiently transducing a nucleic acid of interest into a primary chondrocyte, said gene delivery vehicle is able to at least in part improve the countera ...


10
Havenga Menzo, Vogels Ronald, Bout Abraham: Transduction of dendritic cells using adenoviral vectors. Crucell Holland, Havenga Menzo, Vogels Ronald, Bout Abraham, sKLEIN Bart, March 28, 2002: WO/2002/024730

Adenoviral vectors can be used in vaccines to cause antigen-presenting cells to display desired antigens. Disclosed is a vector and associated means and methods which transduce antigen-presenting cells better than currently available vectors, enabling the vector to be delivered in lower doses, and t ...